UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

Korábbi kezelés

• Patients that are undergoing experimental drug or instrument testing or have participated in other clinical drug trials in the past 3 months.

Más betegség

• Patients who are medically unfit such as those who are haemodynamically unstable or whose general condition is deteriorating.
• Patients who have been diagnosed with malignancy (past or present) or primary haematological disorders.
• Patients diagnosed with brain hemorrhage or other pathological brain disorders such as vascular malformation (brain arteriovenous malformation), tumor, abscess, cardiogenic, inflammatory and infectious cerebral embolism or other common non- ischemic brain diseases, or diagnosed with severe brain atrophy, as determined by CT or MRI scans.
• Patients diagnosed/suspected diagnosis with acute coronary syndrome.
• Patients with congestive cardiac failure.
• Patients with history of confirmed or suspected pulmonary embolism or chronic obstructive pulmonary disease (COPD).
• Patients with mental, cognitive or psychological disorders that affects their understanding and adherence to research procedures and follow-ups.

Laborértékek

• Patients who have renal impairment with serum creatinine more than 200 µmol/l or creatinine clearance less than 30 ml/min.
• Patients who have liver impairment with serum aspartate transaminase (AST) and alanine aminotransferase (ALT) two times greater than upper normal limit.

Egyéb

• Patients with transient ischemic attack (TIA).
• Patients who are pregnant or are breastfeeding.

• Patients must be aged ≥ 18 years old.
• Patients with acute ischemic stroke symptom onset within 4 weeks.
• Patients diagnosed with "moderate to severe" based on NIHSS (6-24) at the time of recruitment.
• Patients who are not eligible for thrombolysis or thrombectomy.
• Written informed consent by the patient or next-of-kin.